Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Inclusion Criteria: * Participants must have radiographically or histologically or cytologically confirmed hepatocellular cancer. Participants must have advanced cancer (metastatic or unresectable) requiring systemic therapy. * Participants must be treated with tremelimumab plus durvalumab and have stable disease or response to therapy. Participants must have received 2 to 5 doses of durvalumab prior to starting treatment on the clinical trial. * Age \>18 years. Because no dosing or adverse event data are currently available on the use of durvalumab in combination with zanzalintinib in participants ≤18 years of age, children are excluded from this study. * ECOG Performance status 0-2. * Participants must have normal organ and marrow function as defined below based upon meeting all the following laboratory criteria within 14 days before first dose of study treatment: * Absolute neutrophil count ≥ 1,500/mcL 1,500/mcL (without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection) * Hemoglobin ≥ 9 g/dL (≥ 90 g/L) without transfusion within 2 weeks prior to screening laboratory sample collection. * Platelet count ≥ 75,000/mcL * Total bilirubin \< 2.0 mg/dL or \<2x upper limit of normal (ULN) whichever is higher * AST (SGOT) ≤ 5 X institutional upper limit of normal * ALT (SGPT) ≤ 5 X institutional upper limit of normal * Creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation * Internat…